MissionIR Articles
-
MissionIRNewsBreaks – SenesTech Inc. (NASDAQ: SNES) Schedules Call, Webcast to Report Q2 2024 Financial Results
SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, has announced plans for a conference call and webcast to be held on Aug. 8, 2024, at 5 p.m. ET. According to the announcement, the company plans to release its financial results for second quarter 2024 after market close on the same day.…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Conference Call, Webcast to Discuss Q2 Results
HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has scheduled a conference call and webcast to discuss its second-quarter 2024 results. According to the announcement, the call is slated to begin at 4:30 p.m. ET on Aug. 14, 2024. HeartBeam executives, including Branislav Vajdic, CEO and…
-
MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Date for Release of Q2 2024 Financial Results
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, will release its financial results for the second quarter of 2024 on Aug. 8, 2024, before the market opens. The financial report will cover the three and six month periods ended June 30, 2024. In addition, the company has scheduled…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) to Participate as an Anchor Organization at the 2024 Southeastern United States – Canadian Provinces Business Forum
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is participating as an Anchor Organization and panelist at the 2024 Southeastern United States – Canadian Provinces (“SEUS-CP”) Business Forum. The 2024 SEUS-CP is set to take place August 4-6 in Biloxi, Mississippi; Mississippi is home to Mullen’s commercial EV manufacturing. Mullen is a confirmed…
-
MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD
InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer’s disease (“AD”) involved seven months of dosing and confirms findings from an earlier short-term pilot…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Inks Exclusive License in ‘Transformational’ Step to Treating GBM
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into an exclusive license agreement with Cortice Biosciences Inc. Through the agreement, CNS Pharmaceuticals has acquired a license as well as the intellectual property rights to a…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Receives Order for Mullen Campus EVs from Leading Transportation and Logistics Company
Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, has received an order for four Mullen Campus electric vehicles from DB Schenker, one of the world’s leading transportation and logistics companies. According to the announcement, the vehicles will be used for mail and delivery on Intel’s technology campus in Chandler, Arizona. The order was received…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Receives PO from European Distributor for 29 Mullen GOs
Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, has received an order for 29 Mullen GOS from one of its newest European distribution partners. The order for the GOs, which are Mullen’s commercial micro-urban-delivery vehicle, came from GAMA, which is a distribution partner covering southeast Europe, including the Balkans Region. The order from GAMA,…
-
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate
Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent covers methods of treating acute traumatic brain injuries (“TBI”) and preventing nerve cell death with its lead drug candidate, buntanetap. Buntanetap (formerly known…
-
MissionIRNewsBreaks – Mullen Automotive Inc.’s (NASDAQ: MULN) Subsidiary Announces Warranty Coverage for B4 Chassis Cab
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced that its subsidiary, Bollinger Motors, released its full warranty coverage on the Bollinger B4 Chassis Cab, the company’s all-new, all-electric Class 4 commercial truck. “We have designed and engineered the Bollinger B4 to have unmatched capability and durability, and we are proud to…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is presenting at the 73rd Emerging Growth Conference, scheduled for…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects and initiatives. With that in mind, the company has named Nelson Cabatuan…
-
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food and Drug Administration (“FDA”) to transition to a new solid form of buntanetap in future clinical trials. “In June 2024, Annovis announced…
-
MissionIRNewsBreaks – Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF) Announces Completion of Business Combination with G Mining Ventures
Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF), a leading gold explorer in the Guiana Shield, has completed its business combination with G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF). The business combination was completed through a court-approved plan of arrangement under the Canada Business Corporations Act after GMIN shareholders and Reunion Gold securityholders approved the plan; the…
-
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering the mark “AVERSA” after completing administrative processes. Nutriband’s proprietary AVERSA(TM) abuse deterrent transdermal technology works…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study
Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting recent study results. According to the announcement, the successful in-vivo preclinical results are from SCNI’s innovative anti IL-17A/F VHH antibody fragment (“NanoAb”),…
-
MissionIRNewsBreaks – Correlate Energy Corp. (CIPI) Expanding Solutions to Significant Untapped Market
Correlate (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform for distributed energy solutions across North America, is strategically working with partners to help clients facilitate green energy transition and improvements. “Correlate Energy is expanding its renewable energy adoption services into a significant untapped market, thanks to a new corporate partnership, a new federal funding…
-
MissionIRNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Positioned as Standout Opportunity for Investors
McEwen Mining’s (NYSE: MUX) (TSX: MUX) share price has shown a remarkable gain of 62.1% over the last 12 weeks, indicating strong momentum and robust performance in the market. “This trend of sustained positive momentum over time is a key indicator of the stock’s potential for continued growth, making it an attractive option for those…
-
MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Significant Improvements from INM-089 in AMD, Validates INM-901 as Potential AD Treatment
InMed (NASDAQ: INM) is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company recently released several critical updates regarding its INM-089 therapy treating dry Age-related Macular Degeneration (“AMD”) and its INM-901 small molecule drug candidate targeting Alzheimer’s disease (“AD”). “Recent preclinical data…
-
MissionIRNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Continues ‘Strong Collaboration’ with New $2.9M Orders from European Governments
SuperCom Ltd. (NASDAQ: SPCB), a global provider of secure solutions for the e-Government, IoT, and cybersecurity sectors, today announced the receipt of new orders from European governments. These orders are valued at $2.9 million and are expected to be delivered in the next four months. According to the announcement, the new orders are the third…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) to Begin Trading as Solmate (NASDAQ: SLMT) on Oct. 3
- Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Builds Domestic Supply Chain Using RapidSX Technology
- Forward Industries Inc. (NASDAQ: FORD) Is ‘One to Watch’
- MissionIRNewsBreaks – Bollinger Innovations, Inc. (NASDAQ: BINI) Signs Agreement to Supply Mullen EVs for FedEx ISP Fleets
- MissionIRNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Sets Standard in High-Performance E-Boat Space